J Cancer 2021; 12(7):1936-1944. doi:10.7150/jca.53675 This issue

Research Paper

Prognostic significance of FSCN family in multiple myeloma

Cong Deng1*, Chaozeng Si2*, Xu Ye3, Qiang Zhou1, Tiansheng Zeng3,4,5, Zeyong Huang3,4,5, Wenhui Huang3,4,5, Pei Zhu3,4,5, Qingfu Zhong3,4,5, Zhihua Wu3,4,5, Huoyan Zhu3,4,5, Qing Lin3,4,5, Wenjuan Zhang3,4,5, Lin Fu3,4,5,6,7✉, Yongjiang Zheng8✉, Tingting Qian3,4,5✉

1. Department of Clinical laboratory, The Second Affiliated Hospital, Guangzhou Medical University, 510260 Guangzhou, China.
2. Department of Information Center, China-Japan Friendship Hospital, 100029 Beijing, China.
3. Department of Hematology, The Second Affiliated Hospital, Guangzhou Medical University, 510260 Guangzhou, China.
4. Translational Medicine Center, State Key Laboratory of Respiratory Disease, The Second Affiliated Hospital of Guangzhou Medical University, 510260 Guangzhou, China.
5. Guangdong Provincial Education Department Key Laboratory of Nano-Immunoregulation Tumor Microenvironment, The Second Affiliated Hospital of Guangzhou Medical University, 510260 Guangzhou, China.
6. Translational Medicine Center, Huaihe Hospital of Henan University, 475000 Kaifeng, China.
7. Department of Hematology, Huaihe Hospital of Henan University, 475000 Kaifeng, China.
8. Department of Hematology, Institute of Hematology, The Third Affiliated Hospital of Sun Yat-Sen University, 510630 Guangzhou, China.
* These authors contributed equally to this work: Cong Deng, Chaozeng Si.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Deng C, Si C, Ye X, Zhou Q, Zeng T, Huang Z, Huang W, Zhu P, Zhong Q, Wu Z, Zhu H, Lin Q, Zhang W, Fu L, Zheng Y, Qian T. Prognostic significance of FSCN family in multiple myeloma. J Cancer 2021; 12(7):1936-1944. doi:10.7150/jca.53675. Available from https://www.jcancer.org/v12p1936.htm

File import instruction

Abstract

Graphic abstract

Multiple myeloma (MM) is a hematologic tumor with monoclonal proliferation of malignant plasma cells in the bone marrow. Fascin (FSCN) is an actin-binding protein that plays a crucial role in cell migration and invasion, contributing to tumor metastasis. There are three members (FSCN1-3) in FSCN family. However, the prognostic role of FSCN family in MM remains unclear. In this study, we used four independent Gene Expression Omnibus (GEO) datasets to explore the relationships between FSCN1-3 expression profiles and patient survival in MM. We found that FSCN1 was dramatically down-regulated in MM compared to normal donors (p < 0.001) and monoclonal gammopathy of undetermined significance (MGUS) (p = 0.032). Patients with high expression of FSCN1 and FSCN2 had significantly longer OS (p = 0.023 and 0.028, respectively). Univariate and multivariate analysis showed that FSCN1 (p = 0.003, 0.002) and FSCN2 (p = 0.018, 0.013) were independent favorable prognostic factors for OS in MM. Moreover, the combination of high expression of FSCN1 and FSCN2 could effectively predict both longer EFS (p = 0.046) and OS (p = 0.015). Our study suggested that FSCN1 and FSCN2 can be used as favorable biomarkers for predicting clinical outcomes in MM.

Keywords: FSCN, multiple myeloma, biomarker, prognosis.